Cancers, Vol. 11, Pages 714: Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Cancers, Vol. 11, Pages 714: Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy Cancers doi: 10.3390/cancers11050714 Authors: Rama Soundararajan Jared Fradette Jessica Konen Stacy Moulder Xiang Zhang Don Gibbons Navin Varadarajan Ignacio Wistuba Debasish Tripathy Chantale Bernatchez Lauren Byers Jeffrey Chang Alejandro Contreras Bora Lim Edwin Parra Emily Roarty Jing Wang Fei Yang Michelle Barton Jeffrey Rosen Sendurai Mani Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has revolutionized the treatment options for cancers such as melanoma. Unfortunately, a significant portion of cancers (including lung and breast cancers) do not respond to immunotherapy, and many of them develop resistance to chemotherapy. Molecular characterization of non-responsive cancers suggest that an embryonic program known as epithelial-mesenchymal transition (EMT), which is mostly latent in adults, can be activated under selective pressures, rendering these cancers resistant to chemo- and immunotherapies. EMT can also drive tumor metastases, which in turn also suppress the cancer-fighting activity of cytotoxic T cells that traffic into the tumor, causing immunotherapy to fail. In this review, we compare and contrast immunotherapy treatment options of non-small cell lung cancer (NSCLC)...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research